A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of Taranabant (MK0364) in Obese Patients Followed by a 1-Year Extension.

Trial Profile

A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of Taranabant (MK0364) in Obese Patients Followed by a 1-Year Extension.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 May 2013

At a glance

  • Drugs Taranabant (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 May 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov
    • 20 Nov 2008 Planned end date changed from 1 Feb 2008 to 1 Feb 2009, reported by ClinicalTrials.gov.
    • 13 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top